chronic spontaneous urticaria
Immunology · 2016–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| omalizumab Treatment of uncontrolled severe asthma (USA), uncontrolled severe allergic asthma (USAA), and severe chronic spontaneous urticaria (CSU). | Mar 2026 | Recommended | input received National Allergy Council · Anaphylaxis Australia · Australasian Society of Clinical Immunology and Allergy |
| omalizumab Treatment of uncontrolled severe asthma (USA) in patients aged 12 years or older, uncontrolled severe allergic asthma (USAA) in patients aged 6 to 12 years,… | Mar 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy · Asthma Australia · National Allergy Council · Anaphylaxis Australia |
| omalizumab Initial and continuing treatment of patients with severe chronic spontaneous urticaria (CSU) who have failed to achieve an adequate response to standard… | Mar 2018 | Recommended with restriction | none received |
| omalizumab Treatment of chronic spontaneous urticaria (CSU) in patients who remain symptomatic despite adequate dose of antihistamine. | Nov 2016 | Recommended | none received |
Who spoke
National Allergy Council · Anaphylaxis Australia · Australasian Society of Clinical Immunology and Allergy · Asthma Australia
What the PBS pays
$51M in government benefit over 2024–25, across 82,658 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| omalizumab | $50.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| omalizumabOmalizumab for previously treated chronic spontaneous urticaria | TA339 | recommended restricted | 2015-06 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| remibrutinibRHAPSIDO remibrutinib 25 mg tablet blister pack | 2026 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.